Disease Detail

Profile Responses 3
Clinical Trials 32

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 3 of 3 entries

Molecular Profile	Therapy	Indication/Tumor Type	Response Type	Profile Response Detail
JAK1 Y654F	Pyridone 6	Sezary's disease	sensitive	detail...
JAK1 Y654F	Ruxolitinib	Sezary's disease	sensitive	detail...
JAK1 Y654F JAK3 A573V	Ruxolitinib	Sezary's disease	sensitive	detail...

Showing 1 to 3 of 3 entries

Filter rows:

Showing 1 to 32 of 32 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02978625	Phase II	Nivolumab + Talimogene laherparepvec	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	Active, not recruiting	USA	0
NCT03011814	Phase Ib/II	Durvalumab Durvalumab + Lenalidomide	Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma	Active, not recruiting	USA	0
NCT03385226	Phase II	Pembrolizumab	A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) (PORT)	Active, not recruiting	GBR	0
NCT03902184	Phase II	Gemcitabine + Lacutamab + Oxaliplatin Lacutamab	IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK)	Active, not recruiting	USA \| POL \| ITA \| FRA \| ESP \| DEU \| BEL \| AUT	0
NCT04401020	Phase I	SAR442257	First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL	Active, not recruiting	USA \| NOR \| ESP \| CZE	1
NCT04652960	Phase I	Duvelisib + Nivolumab	Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome	Active, not recruiting	USA	0
NCT04745234	Phase II	Mogamulizumab	Mogamulizumab Q4week Dosing in Participants With R/R CTCL	Active, not recruiting	USA \| ITA \| GBR \| FRA \| ESP	0
NCT01871727	Phase III	E7777	A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma	Completed	USA \| AUS	1
NCT02581631	Phase Ib/II	Brentuximab vedotin + Nivolumab	A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436)	Completed	USA \| ITA \| GBR \| FRA \| ESP \| CAN	0
NCT02616965	Phase I	Brentuximab vedotin + Romidepsin	A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma	Completed	USA	0
NCT02953301	Phase II	Resminostat	Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (RESMAIN)	Completed	POL \| NLD \| ITA \| GRC \| GBR \| FRA \| ESP \| DEU \| CHE \| BEL \| AUT	1
NCT03063632	Phase II	Interferon gamma + Pembrolizumab	Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome	Completed	USA	0
NCT03695471	Phase II	Pembrolizumab	Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides	Completed	USA	0
NCT04185220	Phase I	Mogamulizumab + rhIL-15	Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome	Completed	USA	0
NCT03081910	Phase I	CD5 CAR-T cells Cyclophosphamide + Fludarabine	Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA)	Recruiting	USA	0
NCT03587844	Phase II	Brentuximab vedotin	Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients	Recruiting	USA	0
NCT03602157	Phase I	ATLCAR.CD30.CCR4 cells Bendamustine + Fludarabine ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells	Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL	Recruiting	USA	0
NCT04234048	Phase I	Fenretinide	Phase 1 Trial of ST-001 NanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma	Recruiting	USA	0
NCT04256018	Phase II	Mogamulizumab	Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sezary Syndrome	Recruiting	USA	0
NCT04752826	Phase Ib/II	BI-1808 + Pembrolizumab BI-1808	BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies(Keynote-D20)	Recruiting	USA \| SWE \| HUN \| GBR \| DNK	1
NCT04930653	Phase II	Mogamulizumab	Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma	Recruiting	USA	0
NCT04960618	Phase II	Gemcitabine + Pembrolizumab	Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sezary Syndrome	Recruiting	USA	0
NCT05079282	Phase I	ONO-4685	Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma	Recruiting	USA	0
NCT05377827	Phase I	WU-CART-007	Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies	Recruiting	USA	0
NCT05414500	Phase I	Brentuximab vedotin + Mogamulizumab	Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides	Recruiting	USA	0
NCT05944562	Phase I	Tulmimetostat	Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sezary Syndrome	Recruiting	USA	0
NCT05967416	Phase I	SIRPant-M	Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma	Recruiting	USA	0
NCT06492304	Phase Ib/II	CTX131	A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies	Recruiting	USA	0
NCT04217317	Phase II	Bendamustine + CPI-613	CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma	Terminated	USA	0
NCT04541017	Phase Ib/II	Hu5F9-G4 Hu5F9-G4 + Mogamulizumab	Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment	Terminated	USA	0
NCT04676087	Phase Ib/II	Mogamulizumab	Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides	Terminated	USA	0
NCT02542124	Phase II	Interleukin-12	NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)	Unknown status	USA	0

Showing 1 to 32 of 32 entries

Filter rows:

ID	DOID:8541
Name	Sezary's disease
Definition
Source	DiseaseOntology.org
Alt Ids	DOID:8790
Path	disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma T-cell non-Hodgkin lymphoma mature T-cell and NK-cell lymphoma peripheral T-cell lymphoma primary cutaneous T-cell non-Hodgkin lymphoma Sezary's disease

Disease Detail

Contact

Filtering

Sorting